Title: Diagnostics in Veterinary Oncology
Presented by: Ariana Verrilli, DVM, DACVIM (Oncology)
Description: This session will discuss the various tests currently available in veterinary oncology, from cytology and histopathology to DNA sequencing and genetic testing. We will review the pros and cons of multiple tests, the best use for each test, and how to interpret results. We will also review sample submissions and specific lab requirements as appropriate.
11. WWW.UVSONLINE.COM
Advantages
Inexpensive
Readily available
Low risk to patient
Fast turnaround time
Evaluate appearance
of individual cells
May give definitive diagnosis
Disadvantages
Small sample
Poor sample quality
Lack of architecture
May not give diagnosis
CYTOLOGY
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
13. WWW.UVSONLINE.COM
Tumor vs. Not
Benign vs. Malignant
Histologic type
Histologic grade (if
appropriate)
Assess surgical margins
HISTOPATHOLOGY
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
14. WWW.UVSONLINE.COM
Identifies antigens that are
relatively specific to one cell
type
Can help ID poorly
differentiated tumors
Likely multiple stains will be
required
Must be used in conjunction
with morphology
IMMUNOHISTOCHEMISTRY
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
15. WWW.UVSONLINE.COM
IHC against:
Melan-A
PNL-2
TRP-1
TRP-2
Highly sensitive and specific
Panel also includes
prognostic markers
MELANOMA PANEL
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
16. WWW.UVSONLINE.COM
Includes:
Ki67 and AgNORs
C-Kit PCR for ITD mutations
in exons 8 & 11
IHC for KIT expression
pattern
Can help predict behavior
and need for adjuvant
treatment
MCT PANEL
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
18. WWW.UVSONLINE.COM
PCR for antigen receptor
rearrangement
Clonality assay
Best for differentiating reactive
from neoplastic lymphocytes or
confirming lymphoid neoplasia
Can be used for
immunophenotyping
PARR
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
19. WWW.UVSONLINE.COM
Analysis of individual cell
properties
Cells must be in suspension
and alive
Primarily hematopoietic
tumors
Provides better
immunophenotyping and
prognostic information
Currently limited use in cats
FLOW CYTOMETRY
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
20. WWW.UVSONLINE.COM
BRAF
Canine urine sample
Evaluates for BRAF
mutation
No present in healthy dogs
or inflammatory conditions
Sensitivity 85%, specificity
100%
BRAF-Plus
Add on test when BRAF is
negative
Looks for specific copy
number variations
Increases sensitivity to 95%
Very low limit of detection
(10 cells)
CADET BRAF
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
21. WWW.UVSONLINE.COM
FidoCure
Extracts tumor DNA for NGS
ID genetic mutations within
tumor
Makes recommendations for
targeted therapies
Can use on formalin-fixed or
fresh biopsy samples
Vidium
Extracts tumor DNA for NGS
Identifies unique mutations
Provides diagnostic, prognostic,
and therapeutic biomarkers
Reports available drug
therapies that target those
mutations
Can use on FNA, formalin-fixed,
or fresh frozen samples
DNA SEQUENCING
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
23. WWW.UVSONLINE.COM
Biological fluids used to
detect CTCs, cfDNA, or
other cellular structures
Prognosis, targetable
mutations, response to
treatment, relapse
Pros & cons
LIQUID BIOPSY
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
24. WWW.UVSONLINE.COM
cfDNA liquid biopsy
Identifies cancer-associated
genomic alterations
Screening or diagnostic test
High specificity; not as
sensitive
Has been positive for 30
different cancers
ONCOK9
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
https://www.veterinarypracticenews.com/clinical-validation-of-oncok9-a-blood-based-multi-cancer-early-detection-liquid-biopsy-test-for-dogs/
25. WWW.UVSONLINE.COM
Nucleosomes released from cancer cells
Measures nucleosomes in blood
Detects 76% of systemic cancers at 97%
specificity
77% lymphoma, 82% hemangiosarcoma,
54% histiocytic sarcoma
Only for dogs, patient must be fasted 4+
hours
Point-of-care option
Screening, diagnosis, response to
treatment
NU.Q®
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
https://vetmed.tamu.edu/gilab/service/assays/nu-q-vet-cancer-screening-test/
27. WWW.UVSONLINE.COM
Chemosensitivity assay
13 most common drugs
Immunophenotyping data
provided
Uses flow cytometry +
PARR + drug sensitivity +
patient data
AI algorithm predicts drug
response
IMPRIMED
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
28. WWW.UVSONLINE.COM
Hypercalcemia:
Most common with
lymphoma or AGASACA
Typically, from production
of PTHrP
Will often note signs of
hyperCa before tumor
symptoms
Panel can help differentiate
causes of hypercalcemia
PTHrP may be negative for
some malignancies
HYPERCALCEMIA OF MALIGNANCY PANEL
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
Diagnosis ICa PTH PTHrP
HCM High Low Positive*
1° HPT High Normal / high Negative
Hypervit D High Low Negative
Granulomatous
disease
High Low Negative
29. WWW.UVSONLINE.COM
Lymphocytosis
Leukemia vs. Stage V
lymphoma
Acute vs. Chronic
Hyperglobulinemia
Plasma cell neoplasia, B cell
neoplasia
Hypercalcemia
Elevated liver enzymes
Azotemia
CBC / CHEMISTRY PANEL
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
30. WWW.UVSONLINE.COM
Lots of different tests
available to help us get a
definitive diagnosis
Can be difficult to know
what tests to use when
New tests are continuing
to come to market
Usefulness of individual
tests will become clearer
with time
REVIEW
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
32. WWW.UVSONLINE.COM
1. Withrow and Macewen’s Small Animal Clinical Oncology. ELSEVIER HEALTH SCIENCES; 2020. Accessed September 16, 2023.
https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso,uid&db=edsgob&AN=edsgob.300950102&site=eds-live&scope=site
2. Nemanic S, London C, Wisner E. Comparison of thoracic radiographs and single breath-hold helical CT for detection of pulmonary nodules in dogs with metastatic neoplasia. JOURNAL OF VETERINARY INTERNAL MEDICINE.
2006;20(3):508-515. Accessed September 11, 2023. https://research-ebsco-com.proxy.library.upei.ca/linkprocessor/plink?id=1cbd8817-e6e0-389a-92a2-5ad2dc41e35e
3. Vail DM, Thamm DH, Reiser H, et al. Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin’s Lymphoma. CLINICAL CANCER RESEARCH. 2009;15(10):3503-3510. Accessed September 18, 2023.
https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso,uid&db=edsbl&AN=RN251841959&site=eds-live&scope=site
4. Meuten DJ, ed. Tumors in Domestic Animals. Fifth edition. John Wiley & Sons Inc.; 2017. Accessed September 18, 2023.
https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso,uid&db=cat01065a&AN=upei.1500264&site=eds-live&scope=site
5. Ramos-Vara JA, Kiupel M, Baszler T, et al. Suggested guidelines for immunohistochemical techniques in veterinary diagnostic laboratories. Journal of Veterinary Diagnostic Investigation. 2008;20(4):393-413. Accessed
September 18, 2023. https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso,uid&db=cbt&AN=20093185790&site=eds-live&scope=site
6. Raskin R, Meyer DJ. Canine and Feline Cytology : A Color Atlas and Interpretation Guide. Vol 3rd edition. Saunders; 2016. Accessed September 19, 2023.
https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso,uid&db=edsebk&AN=1000099&site=eds-live&scope=site
7. Ramos-Vara JA, Miller MA. Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and tyrosinase: Comparison with melan A. Veterinary Pathology. 2011;48(2):443-450-
450. doi:10.1177/0300985810382095
8. Krick EL, Kiupel M, Durham AC, Thaiwong T, Brown DC, Sorenmo KU. Investigating Associations Between Proliferation Indices, C-kit, and Lymph Node Stage in Canine Mast Cell Tumors. Journal of the American Animal Hospital
Association. 2017;53(5):258-264. doi:10.5326/JAAHA-MS-6265
9. Stefano Comazzi, Fulvio Riondato. Flow Cytometry in the Diagnosis of Canine T-Cell Lymphoma. April 2021. Accessed September 20, 2023.
https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso,uid&db=edsago&AN=edsago.DJ20220791381&site=eds-live&scope=site
10. Mochizuki H, Shapiro SG, Breen M. Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma. PloS one. 2015;10(12):e0144170. doi:10.1371/journal.pone.0144170
11. Aghamir SMK, Heshmat R, Ebrahimi M, Khatami F. Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors. Epigenetics Insights. January 2020:1-7. doi:10.1177/2516865720904052
12. Flory A, Kruglyak KM, Tynan JA, et al. Clinical validation of a next-generation sequencing-based multi-cancer early detection “liquid biopsy” blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in
Dogs (CANDiD) study. PLoS ONE. 2022;17(4):1-33. doi:10.1371/journal.pone.0266623
13. Wilson-Robles HM, Bygott T, Kelly TK, et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Veterinary Research. 2022;18(1):1-11. doi:10.1186/s12917-022-
03429-8
14. Koo J, Choi Kyucheol, Lee P, et al. Predicting dynamic clinical outcomes of the chemotherapy for canine lymphoma patients using a machine learning model. Veterinary Sciences. 2021;8(12). doi:https://www.mdpi.com/2306-
7381/8/12/301
REFERENCES:
9/26/2023
DIAGNOSTICS IN VETERINARY ONCOLOGY
Editor's Notes
Top 3 use often
Not using MRI frequently – neuro uses often
PET CT (positron emmision tomography)
Nuclear scintigraphy
- Widely available, relatively inexpensive
Staging, screening, secondary findings / comorbidities, response to therapy / progressive disease
Thoracic radiographs for staging:
are useful for staging – looking for pulmonary metastasis
Can reliably detect pulmonary nodules >9mm in size
Good initial screen test
3 views recommended, allows for capture of most lesions
Mis-diagnosis in 15% of patients with only 2 views
CXR Not mandatory for all tumor types
lymphoma / leukemia – does not necessarily change treatment, may impact prognosis
MCT also not mandatory
Do recommend for all carcinomas, sarcomas, HS, plasma cell neoplasia, melanomas, etc.
Abdominal radiographs not recommended for staging – not enough soft tissue detail
Images: two patients with metastatic pulmonary lesions
Can be used for screening – to evaluate for primary tumors
Useful for diagnosis mediastinal masses
Left - Canine mediastinal mass on left
Right - Feline mediastinal mass on right
For identifying primary lung tumors
Can also be used to evaluate for pleural effusion (carcinomatosis or other)
Abdominal radiographs as screen for primary tumors is more limited
Are unable to ID all tumors or tissue of origin
Used less frequently
Useful for evaluating bone lesions
Left: Primary osteosarcoma distal tibia
Right: Metastatic bone lesions (carcinoma) proximal humerus
Also useful for looking for bone lesions in multiple myeloma cases
Not great at evaluating: skull for nasal / oral / facial tumors
Left: Right: abdomen w/ enlarged LN & thickened GIT dog
Widely available, relatively inexpensive
Screening, staging, assessing response to therapy
Evaluate for comorbidities
Good for:
Abdominal US: primary tumors, metastatic disease, lymphadenopathy
Cervical US: thyroid, LNs, etc.
Thoracic US: mediastinal masses, pulmonary lesions
Echocardiogram for heart based tumors, cardiac HAS, etc.
Sampling tissues w/ ultrasound guidance
AUS useful for staging all tumors
Not mandatory for lymphoma / leukemia – does not necessarily change treatment, may impact prognosis
Important for MCTs / HS/ plasma cell, sarcomas, carcinomas, melanomas
Can also be used for lymph node mapping and other specialized techniques
Left: primary lung tumor; right: osteosarcoma
More sensitive than radiographs at detecting lesions
Best for staging & surgical planning
Thorax
Able to detect pulmonary nodules as small as 1mm – catches what CXR miss
Better at evaluating thoracic LNs vs. CXR
Abdomen:
Able to imaging in pelvis & around gas filled structures
Better imaging for some abdominal tumors (I.e. insulinoma)
US still better for evaluating some abdominal lesions (i.e. GI layering)
Also good way to detect bone lesions – primary and metastatic (60% OSA will develop bone mets)
Much better than radiographs for skull / cervical imaging
Able to better ID tumor extent / margins / tissue invasion
Often important for surgical planning and / or radiation therapy
Better able to delineate tumor boarders vs. Palpation or other imaging modalities
Detect local tumor invasion
Cannot differentiate tumor vs. Tumor associated inflammation
Can also be used for guided sampling of tissues
- Left: MLO
- Right: nasal tumor
MRI: good soft tissue resolution but not widely used outside of CNS tumors
Will sometimes use in conjunction with CT for brain or nasal tumor RT
Nuclear Scintigraphy:
Evaluation of radiopharmaceutical accumulation
Low resolution – limited anatomic detail
Thyroid and bone is where this is used most often
For bone sensitive but not specific – no differentiation between cancer and other bone change
other imaging modality needs to be used in conjunction
Typically not preferred modality
Other imaging modalities work well so not used as often – especially given more ready access to CT scan
Access limited
PET / CT: (image - lymphoma)
Positron emission tomography / computed tomography
Combines function imaging of NS w/ high spacial resolution of CT
Uses radiopharmaceuticals to target areas of interest on scan
Tumors are often hypermetabolic so can be easily targeted them with glucose analogs or other markers
F-18 FDG most common radiopharm– detects increased metabolic activity – not cancer specific
Others available: F-18 NaF for bone lesions; F-18 FLT for proliferating tissues; Cu-ATSM for hypoxic tissues
Likely has similar value in vet patients as humans but is currently not widely available and cost prohibitive
Don't have ready access and cost prohibitive outside of research environment
Useful for:
Obtaining diagnosis / preliminary diagnosis
Staging
Monitoring response to therapy
Detecting recurrence
Advantages
Alone may give definitive diagnosis (i.e. most round cell tumors)
Disadvantages
Small sample – may not be representative of whole tumor or tissue
Poor quality – due to tumor (necrosis, doesn't exfoliate) or technique (lysed cells)
Lack of architecture can make it hard to differentiate inflammatory / neoplastic and benign / malignant tissues
May not give diagnosis (i.e. hepatocellular carcinoma)
Sampling:
Try to get a representative sample (multiple areas or multiple LNs)
Be delicate when smearing – tumor cells are often fragile and can easily rupture (esp. Lymphoma)
Histopath can tell us:
Tumor vs. not
Benign vs. malignant
Histo type and grade
Surgical margins
Pretreatment:
Core, punch, wedge, tru-cut, etc.
obtain additional information before definitive treatment
Posttreatment: excisional biopsy
Gives information about grade, subtype, invasion, margins, etc.
If clinical behavior not matching pathology consider second opinion, special stains, etc.
10% diagnostic disagreement
If histo path doesn't give answers you need --> IHC may be recommended
Image is lingual carcinoma
Antibodies bind antigens that are expressed by certain cell types
A color reaction allows it to be visualized
Can help give definitive diagnosis which can have a big impact on treatment and prognosis
Ex. Oral tumor – r/o OMM vs. Poorly differentiated sarcoma vs. HS
Would treat all very differently!
Quick note on immunocytochemistry
Done in similar way to IHC
Similar panel of markers
Not done as often, limited clinical use
Specificity close to 100%, Sensitivity ~98%
This includes for amelanotic melanomas which are typically the ones we need IHC for
Includes Ki67, nuclear atypia, MC, & degree of pigmentation which are all prognostic
Includes:
Proliferation indices: Ki67 & AgNORs (argyrophilic nucleolar organizer regions)
Ki67 tells about number of proliferating cells
AgNORs relate to speed of proliferation
Combining these 2 tests is predictive of metastasis and survival
Shown that MCTs with low proliferation indices don't need adjuvant therapy even w/ incomplete surgical margins
C-Kit PCR for ITD mutations in exon 8 & 11
Internal tandem duplication mutations
20-30% of cMCTs have ITD in exon 11 --> correlated with more aggressive behavior but respond better to TKIs
2-5% have mutations in exon 8 --> not correlated with behavior, expected to respond to TKIs
IHC for KIT expression pattern
Increased cytoplasmic labeling and loss of membrane-associated labeling --> more aggressive behavior
PCR for antigen receptor rearrangement
Clonality assay --> all cells derived from a single clone
Detects unique genes of an individual B or T lymphocyte that encode the antigen binding region
Detects immunoglobulin gene in B cells and T-cell receptor genes in T cells
If most cells from a node (or multiple nodes or lymphocyte center) have the same receptor gene --> most likely neoplastic, not reactive
A reactive process will have different-sized TCR and immunoglobulin genes
Best for differentiating reactive from neoplastic population
Can be used for immunophenotyping but not as good (i.e. peripheral T cell vs. T-zone)
Very high sensitivity and high specificity for dogs; specificity good for cats but not as sensitive (~60%)
Does have some variation from lab to lab
Analysis of individual cells as they pass in front of a laser
Light absorbance and scatter properties --> cell size and complexity
Can also bind antibodies to look for and quantify intracellular and surface marker expression
Allows for rapid identification of a large number of cells
Most often used for hematopoietic tumors
Cells must be in suspension: anti-coagulated blood or fluids, or FNA suspended in media
Must be shipped overnight --> cells need to be alive on arrival
Cannot always differentiate reactive from neoplastic cells
Can do this if there is aberrant expression of markers (i.e. loss of CD45 in T-zone lymphoma/leukemia)
Does provide better immunophenotyping & prognostic information
I.e. T-zone vs. Peripheral T cell; acute leukemia (CD34+) vs. CLL
Helps differentiate thymoma from cranial mediastinal lymphoma
Thymoma has CD4+ CD8+ lymphocytes --> coexpression only found in thymus
Mediastinal lymphomas will only express one marker – not both
Can be used for peripheral lymphocytosis in cats to help differentiate neoplastic vs. Reactive
For solid tissue samples PARR is more often recommended
Hopefully we will continue to add markers and flow for cats will improve
Uses for BRAF:
Screening high risk patients / breeds
Diagnosis: for patients w/ visible tumor or clinical signs consistent with TCC
Monitoring response: BRAF should decrease as tumor response to treatment, increase w/ progressive disease
NSG = next generation sequencing
FidoCure:
Evaluates tumor DNA for targetable mutations
Makes tx recommendations for targeted drugs available through compounding pharmacy
Provide recommended dose and monitoring plan
Vidium:
Evaluates important mutations in 120+ cancer genes using next-gen sequencing
Both take several weeks for test results
Dog with mandibular osteosarcoma
Biopsy sample submitted to FidoCure – report above
O not interested in surgery or radiation therapy
Unfortunately euthanized before treatment able to be initiated
Results take 2-3 weeks so can be tricky to start therapy quickly
Do offer Data-base results for common tumors
Most common mutations for common tumor --> can start treatments before individual results available
CTCs = circulating tumor cells
Cells that have released from primary tumor and are in circulation
CfDNA = cell free DNA
DNA fragments that are circulating in blood
Other structures: exosomes, nucleosomes
Uses:
Predict prognosis
Reveal targetable mutations
Monitor response to treatment
May detect marker before measurable disease
Pros:
Non-invasive
Easily repeatable
Can use for tumors that cannot be easily sampled
Able to monitor response / relapse earlier than may be clinically evident
Cons:
Very small amounts found in blood
Cannot provide architecture or info on the tumor microenvironment --> still need histopathology
Limited targeted therapies in vet med
Not tumor specific
Screening test:
Use for older dogs or dogs at high risk of developing cancer
Diagnostic test
Use to help confirm cancer when there is a high level of suspicion but not clinically evidence
OR when the tumor is difficult to access
High specificity = 98.5%
If positive your patient has cancer
Lower sensitivity: 85% for top 3 tumors; 55% for all tumor types
Lymphoma, hemangiosarcoma, osteosarcoma – most likely to be positive
Many other types have had positive tests, but not as reliable
For monitoring relapse would need a positive sample at time gross tumor present
Nucleosomes are DNA around a histone protein cores
Released into circulation during apoptosis & necrosis (cancer, severe inflammation, trauma)
Measure by using antibodies specific to neucleosomes
Oral malignant melanoma had high detection rates
Cutaneous melanoma, MCTs, and STS had lowest detection rates
Sensitivity only ~50% overall
Test details:
Collecting data on cats
2-5mLs of EDTA blood
Idexx, Texas A&M GI lab, or point-of-care Heska machine
$200-300, POC test $50
Most patients with a CR will have test results go to negative --> w/ relapse will become positive again
Summary: not all cancers detected, negative result does not mean no cancer, positive result means likely cancer, severe systemic inflammation could result in false positive
For canine lymphoma or leukemia only
Predicts single drug response (image)
Also can predict CHOP failures
Can help select best treatment options
Can be used for naïve or relapse patients
Most common tumors to cause hyperCa = lymphoma, AGASACA
Multiple myeloma, functional parathyroid tumors, thymoma, melanoma, mammary = most common in dogs
Lymphoma, myeloma, squamous cell carcinoma = most common in cats
Multiple others can cause also
Can be caused by other cytokines ( IL-1, IL-6, TNF, calcitriol) or osteolysis
Symptoms: pu/pd, anorexia, vomiting, muscle weakness or twitching
Secondary dehydration, renal damage --> azotemia may/ may not be reversible
If elevated iCa found consider additional diagnostics:
PE including digital rectal exam, malignancy panel, thoracic radiographs, abdominal ultrasound
Most findings are non-specific
CBC:
Lymphocytosis most often
Other leukemias: monocytes, erythrocytosis, etc.
Cytopenias for mylopthesis (myeloma, leukemia, lymphoma, etc.)
Chemistry panel:
Hyperglobulinemia w/ myeloma, B cell
Hypercalcemia (as discussed on other slide)
Elevated liver enzymes – hepatocellular carcinoma, lymphoma, HS, etc.
Azotemia – renal neoplasia (lymphoma, carcinoma, metastatic), TCC, myeloma, leukemia, hypercalcemia